Year : 2022 | Volume
: 27 | Issue : 3 | Page : 279--286
Oral atenolol versus propranolol in the treatment of infantile hemangioma: A systematic review and meta-analysis
Swapnil Annasaheb Pattanshetti1, Vidya M Mahalmani2, Phulen Sarma3, Hardeep Kaur3, Md Mokkaram Ali4, Muneer Abas Malik4, Nitin James Peters4, Manisha Prajapat3, Subodh Kumar3, Bikash Medhi3, Ram Samujh4
1 Department of Paediatric, PGIMER, Chandigarh; Department of Pediatric Surgery, J.N. Medical College, Belgavi, Karnataka, India
2 Department of Pharmacology, PGIMER, Chandigarh; Department of Pharmacology, J.N. Medical College, Belgavi, Karnataka, India
3 Department of Pharmacology, PGIMER, Chandigarh, India
4 Department of Paediatric Surgery, PGIMER, Chandigarh, India
Background: Infantile hemangioma (IH) is the most common benign vascular tumor of infancy. Propranolol is considered first-line therapy for IH. However, it is associated with side effects. Therefore, there was a need for alternative therapy. Atenolol, a selective b1-blocker may be free from such side effects. Hence, the present study aims to develop a more accurate estimate of the safety and efficacy of atenolol compared to propranolol in the treatment of IH.
Methodology: A search of various literature databases (PubMed, Embase, Ovid, Scopus, Cochrane Central, CINAHL, Web of Science, and Google Scholar) was done to identify studies which compared propranolol versus atenolol in the treatment of IH. The combined odds ratio along with corresponding 95% confidence intervals (CIs) were evaluated using a fixed-effects model.
Results: A total of 300 articles were screened of which five studies including 116 patients in atenolol arm and 138 patients in the propranolol arm were analyzed. Atenolol was comparable to propranolol in terms of efficacy as no significant difference was seen between both the treatment arms in terms of hemangioma activity score (mean difference 0.25 [95% CI;‒0.21, 0.71]) and complete response (odds ratio [OR] =0.43; 95% CI; 0.17, 1.11; P = 0.08,). Atenolol therapy was better than propranolol in terms of safety, i.e., serious/potentially serious side effect, (OR = 0.11; 95% CI; 0.02, 0.51; P = 0.005) and wheezing/bronchial hyperreactivity (OR = 0.11; 95% CI; 0.02, 0.51; P = 0.005).
Conclusion: The present meta-analysis provides evidence that atenolol has got a comparable efficacy and better safety profile with propranolol
Dr. Ram Samujh
Department of Pediatric Surgery, PGIMER, Chandigarh
|How to cite this article:|
Pattanshetti SA, Mahalmani VM, Sarma P, Kaur H, Ali MM, Malik MA, Peters NJ, Prajapat M, Kumar S, Medhi B, Samujh R. Oral atenolol versus propranolol in the treatment of infantile hemangioma: A systematic review and meta-analysis.J Indian Assoc Pediatr Surg 2022;27:279-286
|How to cite this URL:|
Pattanshetti SA, Mahalmani VM, Sarma P, Kaur H, Ali MM, Malik MA, Peters NJ, Prajapat M, Kumar S, Medhi B, Samujh R. Oral atenolol versus propranolol in the treatment of infantile hemangioma: A systematic review and meta-analysis. J Indian Assoc Pediatr Surg [serial online] 2022 [cited 2022 May 22 ];27:279-286
Available from: https://www.jiaps.com/article.asp?issn=0971-9261;year=2022;volume=27;issue=3;spage=279;epage=286;aulast=Pattanshetti;type=0